liraglutide glp 1 agonist A rising tide with Generic Liraglutide (Victoza) Becomes First

Targeted ablation of glucosedependent insulinotropic polypeptideproducing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet

Month-to-month billing (no multi-month commitment required)

Of late, attention has been focused on the role that GIP plays in maintaining metabolic homeostasis, most likely in concert with GLP-1

Indications: FDA approved: Type II diabetes - monotherapy or combination therapy Can be combined as adjunct therapy with other hypoglycemics including metformin, thiazolidinediones, or insulin regimens (Dungan & DeSantis 2015) Because it does not work when your blood sugar is low, it is unlikely to produce dangerous levels of hypoglycemia has been observed in clinical trials (in contrast to GLP-1 incretin mimetics, such as exenatide, which produce moderate weight loss)